We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
78 hedge funds and large institutions have $535M invested in Crescent Biopharma in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 31 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
1% more funds holding
Funds holding: 77 → 78 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 1.05% → 1.04% (-0.01%)
6% less capital invested
Capital invested by funds: $567M → $535M (-$31.2M)
23% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 31
95% less call options, than puts
Call options by funds: $74K | Put options by funds: $1.45M
Holders
78
Holders Change
+1
Holders Change %
+1.3%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
24
Reduced
31
Closed
6
Calls
$74K
Puts
$1.45M
Net Calls
-$1.38M
Net Calls Change
-$1.54M
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
+$57M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$4.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.7M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.44M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.88M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.42M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.15M |
